Clinical Trial Update: Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11% [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of vildagliptin in adults with type 2 diabetes and HbA1c 9-11% has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED